Language:

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy

Drug design, development and therapy, 2020-01, Vol.14, p.4775-4788 [Peer Reviewed Journal]

COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Li and Zhou. 2020 Li and Zhou. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S269514 ;PMID: 33192053

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
Author: Li, Na ; Zhou, Hong
Subjects: Aldosterone ; Angiotensin ; Apoptosis ; Blood pressure ; Cardiomyocytes ; Cardiomyopathy ; cardioprotection ; Cardiovascular disease ; Cardiovascular diseases ; Care and treatment ; Clinical trials ; Congestive heart failure ; Coronary artery disease ; Coronary heart disease ; Coronary vessels ; Development and progression ; Dextrose ; Diabetes ; Diabetes mellitus ; diabetic cardiomyopathy ; Diabetics ; Drugs ; Ejection fraction ; Endoplasmic reticulum ; Fibrosis ; Glucose ; Health aspects ; Health risks ; Heart ; Heart diseases ; Homeostasis ; Hyperglycemia ; Hypertension ; Hypoglycemia ; Hypoglycemic agents ; Inflammation ; Inhibitors ; Insulin ; Li Na ; Metabolism ; Mitochondria ; molecular mechanism ; Molecular modelling ; Mortality ; Oxidative stress ; Pathophysiology ; Patients ; Prevention ; Renin ; Review ; sglt2 inhibitor ; Sodium ; Uric acid
Is Part Of: Drug design, development and therapy, 2020-01, Vol.14, p.4775-4788
Description: Diabetic cardiomyopathy (DCM) characterized by diastolic and systolic dysfunction independently of hypertension and coronary heart disease, eventually develops into heart failure, which is strongly linked to a high prevalence of mortality in people with diabetes mellitus (DM). Sodium-glucose cotransporter type2 inhibitors (SGLT2Is) are a novel type of hypoglycemic agent in increasing urinary glucose and sodium excretion. Excitingly, the EMPA-REG clinical trial proved that empagliflozin significantly reduced the relative risk of cardiovascular (CV) death and hospitalization for heart failure (HHF) in patients with type 2 DM (T2DM) plus CV disease (CVD). The EMPRISE trial showed that empagliflozin decreased the risk of HHF in T2DM patients with and without a CVD history in routine care. These beneficial effects of SGLT2Is could not be entirely attributed to glucose-lowering or natriuretic action. There could be potential direct mechanisms of SGLT2Is in cardioprotection. Recent studies have shown the effects of SGLT2Is on cardiac iron homeostasis, mitochondrial function, anti-inflammation, anti-fibrosis, antioxidative stress, and renin-angiotensin-aldosterone system activity, as well as GlcNAcylation in the heart. This article reviews the current literature on the effects of SGLT2Is on DCM in preclinical studies. Possible molecular mechanisms regarding potential benefits of SGLT2Is for DCM are highlighted, with the purpose of providing a novel strategy for preventing DCM. Keywords: diabetes, diabetic cardiomyopathy, SGLT2 inhibitor, cardioprotection, molecular mechanism
Publisher: Macclesfield: Dove Medical Press Limited
Language: English
Identifier: ISSN: 1177-8881
EISSN: 1177-8881
DOI: 10.2147/DDDT.S269514
PMID: 33192053
Source: Open Access: DOAJ Directory of Open Access Journals
Open Access: PubMed Central
Geneva Foundation Free Medical Journals at publisher websites
AUTh Library subscriptions: ProQuest Central
ROAD: Directory of Open Access Scholarly Resources
Dove Press Free

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy

Searching Remote Databases, Please Wait